Key result
The utility of cardiac biomarkers in the assessment of adult congenital heart disease is still being evaluated, despite their proven role in acquired heart disease.
Why the study?
What is the utility of cardiac biomarkers in the management of adults with congenital heart disease?
What is the utility of cardiac biomarkers in the management of adults with congenital heart disease?
While cardiac biomarkers have proven utility in acquired heart failure, their role in the management of adult congenital heart disease is still under investigation.
Biomarker-guided management in adult CHD lacks established evidence; leaves open the need for prospective validation before clinical adoption.
The population of adults with congenital heart disease (CHD) now exceeds the population of children with CHD. The long-term management of these patients relies on sequential assessment of anatomy and physiology and integration with symptoms, all targeted toward decision making around intervention. The advances in technology have vastly improved our assessment of anatomy and function. However, while the assessment of chronic heart failure in acquired heart disease has been revolutionized by the proven utility of cardiac biomarkers, their use in adult CHD is still being assessed.
No takes yet. Share an insight, caveat, or question.
Walker et al. (2014) conducted a review in Congenital heart disease. Cardiac biomarkers was evaluated. The utility of cardiac biomarkers in the assessment of adult congenital heart disease is still being evaluated, despite their proven role in acquired heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: